Keynote Speakers
Dr. Noubar Afeyan
Co-Founder and Chairman, Moderna
Founder and CEO of Flagship Pioneering
Moderna, Pandemic Vaccines, and the Path to Health Security
Dr. Noubar Afeyan is founder and CEO of Flagship Pioneering, an enterprise where entrepreneurially minded scientists invent pioneering solutions to challenges facing human health and sustainability. In 2020 Dr. Afeyan has started clinical trials of a novel coronavirus vaccine in Seattle, Washington.

Dr. Afeyan is a lecturer at Harvard Business School; and from 2000 to 2016 was a senior lecturer at MIT’s Sloan School of Management where he taught courses on technology-entrepreneurship, innovation, and leadership. He teaches and speaks around the world on topics ranging from entrepreneurship, innovation, and economic development to biological engineering, new medicines, and renewable energy. Noubar currently serves on the boards of a number of public and private Flagship companies, including Moderna (NASDAQ: MRNA), where he is chairman, Rubius Therapeutics (NASDAQ:RUBY), Cellarity, Omega Therapeutics, Tessera Therapeutics, and others.

He was founder and CEO of PerSeptive Biosystems, a leader in bio-instrumentation that grew to $100 million in annual revenues. Dr. Afeyan has co-founded and helped build over 40 life science and technology startups during his career as an inventor, entrepreneur, and CEO.

Dr. Masaaki Mochimaru
General Manager, AIST
Human Augmentation Technologies towards Competence Sharing through Augmented Telework

Masaaki Mochimaru studied Mechanical Engineering and Ergonomics at Keio University in Japan, where he received PhD in Engineering. In 1993, he joined AIST as a researcher. In 2001, he was assigned as the deputy director of Digital Human Laboratory of AIST. In 2010, he launched and directed Digital Human Research Center of AIST. After November 2018, he directs a new research center, Human Augmentation Research Center of AIST. His research interests are related to measurement and modeling of human functions and their applications. In recent years, his research interests are expanded to service engineering and servitization.

Claire Delaunay
A robotics perspective in the age of COVID-19

Claire Delaunay is vice president of engineering at NVIDIA, where she is responsible for the Isaac robotics initiative and leads a team to bring Isaac to market for roboticists and developers around the world. Prior to joining NVIDIA, Delaunay was the director of engineering at Uber, after it acquired Otto, the startup she co-founded. She was also the robotics program lead at Google and founded two companies, Botiful and Robotics Valley. Delaunay has 15 years of experience in robotics and autonomous vehicles leading teams ranging from startups and research labs to Fortune 500 companies. Delaunay holds a Master of Science in computer engineering from École Privée des Sciences Informatiques (EPSI).

Dr. Simon Marvin
Professor, University of Sheffield
Biosecure Urbanism: Covid-19, New Technologies and the Future of Cities

Professor Simon Marvin, Director the Urban Institute, University of Sheffield. An internationally renowned urban scholar, his work develops innovative, interdisciplinary perspectives that examine the interrelations between technological change and urban life. His latest book with Andres Luque-Ayala is “Urban Operating Systems: Producing the Computational City” published by MIT press in December 2020. Drawing on fieldwork that stretches across eleven cities in American, European, and Asian contexts, Urban OS investigates how digital products, services, and ecosystems are reshaping the ways in which the city is imagined, known, and governed.

Katherine (Kathy) Winter
Vice President and General Manager​​​​​​​, Intel
Big Bets and Building Blocks: Enriching lives through smart and autonomous solutions

Kathy manages a global organization, which delivers comprehensive solutions for Smart Cities, Mobile Automation and Transportation. She leads a team that is developing increasingly sophisticated platforms for a variety of commercial and consumer market segments, including: Advanced Driver Assist Systems (ADAS) and Autonomous Driving (AD), Automated Mobile Robots (AMR), In Vehicle Infotainment (IVI), Fleets, Rail, Road, Marine, and Airports. Kathy is seen as an expert in the field, she was recognized by EETimes as part of its Women in Tech: 25 Profiles in Persistence in 2017, she was named one of the most powerful female engineers by Business Insider in 2018, and most recently was announced as a recipient of the Connected World 2020 Women of Technology and IOT.

Dr. Ying Chi
Director of DAMO Academy Medical AI
Alibaba DAMO Academy Medical & Health AI Technology and Practices Against COVID-19
Dr Ying Chi is a premier algorithm expert (IEEE Senior Member) with Alibaba DAMO Academy AI Center for Healthcare Intelligence. She received her Ph.D. in Bioengineering from Imperial College London, UK, followed by postdoctoral research at the Institute of Biomedical Engineering, Oxford University, UK. Prior to Alibaba, she worked as China Medical AI Head at Siemens. Her doctoral thesis was awarded the Best Paper at the Annual Meeting of the European Magnetic Resonance Society. She also won the Old Centralien’s Innovation Award from the City of London, and the Imperial College Excellence in Innovation Award. After joining Alibaba, she has been leading the medical team at the AI Center of Alibaba Damo Academy where her research has won several international challenges. In response to the COVID-19 outbreak, she has led the medical AI team at Alibaba developing various AI products (CT image analysis, whole-genome sequencing analysis, epidemic prediction, response to questions based on knowledge graphs, and video translation on a knowledge exchange platform). Part of the code developed by her group for CT image analysis has been in collection of National Museum of China, and the first CT data used have been in collection of National Science and Technology Museum of China. The products developed by her team are deployed in over 90 hospitals in Japan and >530 hospitals in China. Her current research focus is on medical imaging, picture analysis, natural language processing, gene, protein, and pharmaceutical development.